Sherlock Biosciences has raised $80 million in a financing to help enhance its point-of-care diagnostics offerings.
The series B round was led by Novalis LifeSciences and included new investors Illumina Ventures, Albany Capital and Catalio Capital Management, among others. They joined Northpond Ventures, Good Ventures, and other existing investors.
To date, the Boston, MA-based company has raised $111 million.
Powered by CRISPR and synthetic biology, Sherlock's proprietary engineering biology tools form the foundation of its decentralized diagnostic platform for DNA and RNA detection. This new funding will drive development of products and partnerships, enabled by this platform, that can operate at ambient temperature without complex instrumentation, opening up a wide range of applications in low resource settings including the home.
"Sherlock is dedicated to breaking down diagnostic barriers and bringing health information to people around the world," said Bryan Dechairo, President and CEO of Sherlock Biosciences. "Our novel chemistries combine the accuracy of PCR with the simplicity and convenience of antigen tests, powering a decentralized diagnostic platform for DNA and RNA detection. We are grateful to our funding partners for supporting our mission to ignite a convenience revolution in healthcare and further global public health."